Medscape | European Regulators Back Biosimilar Antibodies Medscape This is notable because antibodies are inherently difficult to replicate and are subject to posttranslational modifications, such as glycosylation. They also may be heterogenous and often include subtle variants. Tight manufacturing controls ... A Landmark For Biosimilars: EU Endorses Copies Of A J and J Drug 'Biosimilar' drug ruling to hit Big Pharma Billion-dollar biotech drug may soon have biosimilar competition |
